The use of different doses levonorgestrel-releasing intrauterine system (LNG-IUS): real-world data from a multicenter Italian study

References

• Grandi G, Farulla A, Sileo FG, et al. Levonorgestrel-releasing intra-uterine systems as female contraceptives. Expert Opin Pharmacother. 2018;19(7):677–668.
   PubMed Web of Science ®Google Scholar
• Apter D, Gemzell-Danielsson K, Hauck B, et al. Pharmacokinetics of two low-dose levonorgestrel-releasing intrauterine systems and effects on ovulation rate and cervical function: pooled analyses of phase II and III studies. Fertil Steril. 2014;101(6):1656–1662.e1-4.
   PubMed Web of Science ®Google Scholar
• Nelson A, Apter D, Hauck B, et al. Two low-dose levonorgestrel intrauterine contraceptive systems: a randomized controlled trial. Obstet Gynecol. 2013;122(6):1205–1213.
   PubMed Web of Science ®Google Scholar
• Trussell J, Hassan F, Henry N, et al. Cost-effectiveness analysis of levonorgestrel-releasing intrauterine system (LNG-IUS) 13.5 mg in contraception. Contraception. 2014;89(5):451–459.
   PubMed Web of Science ®Google Scholar
• Nilsson CG, Luukkainen T, Diaz J, et al. Intrauterine contraception with levonorgestrel: a comparative randomised clinical performance study. Lancet. 1981;1(8220 Pt 1):577–580.
   PubMed Web of Science ®Google Scholar
• Jensen JT, Nelson AL, Costales AC, et al. Subject and clinician experience with the levonorgestrel-releasing intrauterine system. Contraception. 2008;77(1):22–29.
   PubMed Web of Science ®Google Scholar
• Grandi G, De Fata R, Varliero F, et al. Contemporary prescriptions pattern of different dose levonorgestrel-releasing intrauterine systems in an italian service for family planning. Gynecol Endocrinol. 2020;36(12):1086–1089.
   PubMed Web of Science ®Google Scholar
• Goldstuck ND. Clarification of the role of the Jaydess(Skyla) LNG- IUS 13.5mg and Kyleena LNG-IUS 19.5mg as intrauterine contraceptive systems. Expert Rev Med Devices. 2017;14(8):593–599.
   PubMed Web of Science ®Google Scholar
• Serfaty D, Bénézech JP, Heckel S, et al. Consensus of best practice in intrauterine contraception in France. Eur J Contracept Reprod Health Care. 2019;24(4):305–313.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Medical eligibility criteria for contraceptive use. 5th ed. Geneva: WHO; 2015.
   Google Scholar
• Levine D, Patel MD, Suh-Burgmann EJ, et al. Simple adnexal cysts: SRU consensus conference update on follow-up and reporting. Radiology. 2019;293(2):359–371.
   PubMed Web of Science ®Google Scholar
• Patseadou M, Michala L. Usage of the levonorgestrel-releasing intrauterine system (LNG-IUS) in adolescence: what is the evidence so far? Arch Gynecol Obstet. 2017;295(3):529–541.
   PubMed Web of Science ®Google Scholar
• Gemzell-Danielsson K, Schellschmidt I, Apter D. A randomized, phase II study describing the efficacy, bleeding profile, and safety of two low-dose levonorgestrel-releasing intrauterine contraceptive systems and Mirena. Fertil Steril. 2012;97(3):616–22e1–3.
   PubMed Web of Science ®Google Scholar
• Dickerson LM, Diaz VA, Jordon J, et al. Satisfaction, early removal and side effects associated with long-acting reversible contraception. Fam Med. 2013;45(10):701–707.
   PubMed Web of Science ®Google Scholar
• Hall AM, Kutler BA. Intrauterine contraception in nulliparous women: a prospective survey. J Fam Plann Reprod Health Care. 2016;42(1):36–42.
   PubMedGoogle Scholar
• Soriano LC, Wallander M, Andersson S, et al. The continuation rates of long-acting reversible contraceptives in UK general practice using data from the health improvement network. Pharmacoepidemiol Drug Saf. 2015;24(1):52–58.
   PubMed Web of Science ®Google Scholar
• Teunissen AM, Merry AHH, Devies IEC, et al. Differences in continuation rates and early removal between contraceptive and therapeutic use of the levonorgestrel-releasing intrauterine system 52 mg. Eur J Contracept Reprod Health Care. 2019;24(6):449–456.
   PubMed Web of Science ®Google Scholar
• Gemzell-Danielsson K, Inki P, Heikinheimo O. Recent developments in the clinical use of the levonorgestrel-releasing intrauterine system. Acta Obstet Gynecol Scand. 2011;90(11):1177–1188.
   PubMed Web of Science ®Google Scholar
• O’Neil ME, Jeffrey FP, Qiuhong Z, et al. Twenty-four-month continuation of reversible contraception. Obstet Gynecol. 2013;122:1083–1091.
   PubMed Web of Science ®Google Scholar
• Rosenstock JR, Jeffrey FP, Madden T, et al. Continuation of reversible contraception in teenagers and young women. Obstet Gynecol. 2012;120:1298–1305.
   PubMed Web of Science ®Google Scholar
• Peipert JF, Zhao Q, Allsworth JE, et al. Continuation and satisfaction of reversible contraception. Obstet Gynecol. 2011;117(5):1105–1113.
   PubMed Web of Science ®Google Scholar
• Gemzell-Danielsson K, Apter D, Dermout S, et al. Evaluation of a new, low-dose levonorgestrel intrauterine contraceptive system over 5 years of use. Eur J Obstet Gynecol Reprod Biol. 2017;210:22–28.
   PubMed Web of Science ®Google Scholar
• Frenz AK, Ahlers C, Beckert V, et al. Predicting menstrual bleeding patterns with levonorgestrel-releasing intrauterine systems. Eur J Contracept Reprod Health Care. 2021;26(1):48–57.
   PubMed Web of Science ®Google Scholar
• Nahum GG, Kaunitz AM, Rosen K, et al. Ovarian cysts: presence and persistence with use of a 13.5mg levonorgestrel-releasing intrauterine system. Contraception. 2015;91(5):412–417.
   PubMed Web of Science ®Google Scholar
• Inki P, Hurskainen R, Palo P, et al. Comparison of ovarian cyst formation in women using the levonorgestrel-releasing intrauterine system vs. hysterectomy. Ultrasound Obstet Gynecol. 2002;20(4):381–385.
   PubMed Web of Science ®Google Scholar
• Hidalgo MM, Lisondo C, Juliato CT, et al. Ovarian cysts in users of implanon and jadelle subdermal contraceptive implants. Contraception. 2006;73(5):532–536.
   PubMed Web of Science ®Google Scholar
• Borgfeldt C, Andolf E. Transvaginal sonographic ovarian findings in a random sample of women 25-40 years old. Ultrasound Obstet Gynecol. 1999;13(5):345–350.
   PubMed Web of Science ®Google Scholar
• Järvelä I, Tekay A, Jouppila P. The effect of a levonorgestrel-releasing intrauterine system on uterine artery blood flow, hormone concentrations and ovarian cyst formation in fertile women. Hum Reprod. 1998;13(12):3379–3383.
   PubMed Web of Science ®Google Scholar